ReviewDiscover oncology2026
Targeting glutamine metabolism to modulate macrophage functions in the tumor microenvironment.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic licensing and restriction of innate immunity in the tumor microenvironment.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The increased glutamine demand of malignant cells imposes profound metabolic pressure on immune cells, particularly macrophages, forcing adaptive changes in their glutamine utilization pathways. This metabolic reprogramming involves three interconnected processes, namely, glutamine biosynthesis, catabolic breakdown, and cellular uptake, which are precisely regulated by specialized enzymes, metabolic intermediates, and membrane transport systems. As a pivotal area in modern oncology, glutamine metabolism serves as a master regulator of macrophage biology, simultaneously governing their bioenergetic requirements and immunological competence, thereby critically influencing tumor progression and metastatic potential. Our examination further reveals the intricate involvement of glutamine metabolic pathways in shaping the immunosuppressive tumor microenvironment and their dynamic interactions with host anti-tumor immune responses. These insights illuminate the therapeutic potential of targeting glutamine metabolism as an innovative strategy to improve cancer treatment paradigms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.